id	sid	tid	token	lemma	pos
dpc-4042	1	1	dermatology	dermatology	NOUN
dpc-4042	1	2	:	:	PUNCT
dpc-4042	1	3	practical	practical	ADJ
dpc-4042	1	4	and	and	CCONJ
dpc-4042	1	5	conceptual	conceptual	ADJ
dpc-4042	1	6	research	research	NOUN
dpc-4042	1	7	letter	letter	NOUN
dpc-4042	2	1	|	|	ADV
dpc-4042	2	2	dermatol	dermatol	ADJ
dpc-4042	2	3	pract	pract	NOUN
dpc-4042	2	4	concept	concept	NOUN
dpc-4042	2	5	.	.	PUNCT
dpc-4042	3	1	2024;14(2):e2024137	2024;14(2):e2024137	NUM
dpc-4042	3	2	1	1	NUM
dpc-4042	3	3	retrospective	retrospective	ADJ
dpc-4042	3	4	cohort	cohort	NOUN
dpc-4042	3	5	study	study	NOUN
dpc-4042	3	6	of	of	ADP
dpc-4042	3	7	hepatic	hepatic	ADJ
dpc-4042	3	8	and	and	CCONJ
dpc-4042	3	9	hematologic	hematologic	NOUN
dpc-4042	3	10	toxicity	toxicity	NOUN
dpc-4042	3	11	in	in	ADP
dpc-4042	3	12	terbinafine	terbinafine	ADV
dpc-4042	3	13	-	-	PUNCT
dpc-4042	3	14	treated	treat	VERB
dpc-4042	3	15	onychomycosis	onychomycosis	NOUN
dpc-4042	3	16	patients	patient	NOUN
dpc-4042	3	17	with	with	ADP
dpc-4042	3	18	reduced	reduce	VERB
dpc-4042	3	19	kidney	kidney	NOUN
dpc-4042	3	20	function	function	NOUN
dpc-4042	3	21	at	at	ADP
dpc-4042	3	22	an	an	DET
dpc-4042	3	23	academic	academic	ADJ
dpc-4042	3	24	institution	institution	NOUN
dpc-4042	3	25	kaya	kaya	PROPN
dpc-4042	3	26	l.	l.	PROPN
dpc-4042	3	27	curtis1	curtis1	PROPN
dpc-4042	3	28	,	,	PUNCT
dpc-4042	3	29	jose	jose	PROPN
dpc-4042	3	30	w.	w.	PROPN
dpc-4042	3	31	ricardo2	ricardo2	PROPN
dpc-4042	3	32	,	,	PUNCT
dpc-4042	3	33	yuqing	yuqe	VERB
dpc-4042	3	34	qiu3	qiu3	NOUN
dpc-4042	3	35	,	,	PUNCT
dpc-4042	3	36	debra	debra	PROPN
dpc-4042	3	37	k.	k.	PROPN
dpc-4042	3	38	lee4	lee4	PROPN
dpc-4042	3	39	,	,	PUNCT
dpc-4042	3	40	jamie	jamie	PROPN
dpc-4042	3	41	hedrick5	hedrick5	PROPN
dpc-4042	3	42	,	,	PUNCT
dpc-4042	3	43	henry	henry	PROPN
dpc-4042	3	44	i.	i.	PROPN
dpc-4042	3	45	lipner6	lipner6	PROPN
dpc-4042	3	46	,	,	PUNCT
dpc-4042	3	47	shari	shari	PROPN
dpc-4042	3	48	r.	r.	PROPN
dpc-4042	3	49	lipner2	lipner2	PROPN
dpc-4042	3	50	1	1	NUM
dpc-4042	3	51	weill	weill	PROPN
dpc-4042	3	52	cornell	cornell	PROPN
dpc-4042	3	53	medical	medical	PROPN
dpc-4042	3	54	college	college	PROPN
dpc-4042	3	55	,	,	PUNCT
dpc-4042	3	56	new	new	PROPN
dpc-4042	3	57	york	york	PROPN
dpc-4042	3	58	,	,	PUNCT
dpc-4042	3	59	new	new	PROPN
dpc-4042	3	60	york	york	PROPN
dpc-4042	3	61	,	,	PUNCT
dpc-4042	3	62	usa	usa	PROPN
dpc-4042	3	63	2	2	NUM
dpc-4042	3	64	weill	weill	PROPN
dpc-4042	3	65	cornell	cornell	PROPN
dpc-4042	3	66	medicine	medicine	NOUN
dpc-4042	3	67	,	,	PUNCT
dpc-4042	3	68	department	department	NOUN
dpc-4042	3	69	of	of	ADP
dpc-4042	3	70	dermatology	dermatology	NOUN
dpc-4042	3	71	,	,	PUNCT
dpc-4042	3	72	new	new	PROPN
dpc-4042	3	73	york	york	PROPN
dpc-4042	3	74	,	,	PUNCT
dpc-4042	3	75	new	new	PROPN
dpc-4042	3	76	york	york	PROPN
dpc-4042	3	77	,	,	PUNCT
dpc-4042	3	78	usa	usa	PROPN
dpc-4042	3	79	3	3	NUM
dpc-4042	3	80	department	department	PROPN
dpc-4042	3	81	of	of	ADP
dpc-4042	3	82	population	population	PROPN
dpc-4042	3	83	health	health	PROPN
dpc-4042	3	84	sciences	sciences	PROPN
dpc-4042	3	85	,	,	PUNCT
dpc-4042	3	86	weill	weill	PROPN
dpc-4042	3	87	cornell	cornell	PROPN
dpc-4042	3	88	medicine	medicine	PROPN
dpc-4042	3	89	,	,	PUNCT
dpc-4042	3	90	new	new	PROPN
dpc-4042	3	91	york	york	PROPN
dpc-4042	3	92	,	,	PUNCT
dpc-4042	3	93	new	new	PROPN
dpc-4042	3	94	york	york	PROPN
dpc-4042	3	95	,	,	PUNCT
dpc-4042	3	96	usa	usa	PROPN
dpc-4042	3	97	4	4	NUM
dpc-4042	3	98	university	university	PROPN
dpc-4042	3	99	of	of	ADP
dpc-4042	3	100	texas	texas	PROPN
dpc-4042	3	101	medical	medical	PROPN
dpc-4042	3	102	branch	branch	PROPN
dpc-4042	3	103	,	,	PUNCT
dpc-4042	3	104	galveston	galveston	PROPN
dpc-4042	3	105	,	,	PUNCT
dpc-4042	3	106	texas	texas	PROPN
dpc-4042	3	107	,	,	PUNCT
dpc-4042	3	108	usa	usa	PROPN
dpc-4042	3	109	5	5	NUM
dpc-4042	3	110	philadelphia	philadelphia	PROPN
dpc-4042	3	111	college	college	NOUN
dpc-4042	3	112	of	of	ADP
dpc-4042	3	113	osteopathic	osteopathic	ADJ
dpc-4042	3	114	medicine	medicine	NOUN
dpc-4042	3	115	,	,	PUNCT
dpc-4042	3	116	philadelphia	philadelphia	PROPN
dpc-4042	3	117	,	,	PUNCT
dpc-4042	3	118	pennsylvania	pennsylvania	PROPN
dpc-4042	3	119	,	,	PUNCT
dpc-4042	3	120	usa	usa	PROPN
dpc-4042	3	121	6	6	NUM
dpc-4042	3	122	division	division	NOUN
dpc-4042	3	123	of	of	ADP
dpc-4042	3	124	nephrology	nephrology	NOUN
dpc-4042	3	125	,	,	PUNCT
dpc-4042	3	126	maimonides	maimonides	PROPN
dpc-4042	3	127	medical	medical	PROPN
dpc-4042	3	128	center	center	PROPN
dpc-4042	3	129	,	,	PUNCT
dpc-4042	3	130	brooklyn	brooklyn	PROPN
dpc-4042	3	131	,	,	PUNCT
dpc-4042	3	132	new	new	PROPN
dpc-4042	3	133	york	york	PROPN
dpc-4042	3	134	,	,	PUNCT
dpc-4042	3	135	usa	usa	PROPN
dpc-4042	3	136	key	key	NOUN
dpc-4042	3	137	words	word	NOUN
dpc-4042	3	138	:	:	PUNCT
dpc-4042	3	139	terbinafine	terbinafine	ADJ
dpc-4042	3	140	,	,	PUNCT
dpc-4042	3	141	onychomycosis	onychomycosis	NOUN
dpc-4042	3	142	,	,	PUNCT
dpc-4042	3	143	renal	renal	ADJ
dpc-4042	3	144	,	,	PUNCT
dpc-4042	3	145	hepatic	hepatic	NOUN
dpc-4042	3	146	,	,	PUNCT
dpc-4042	3	147	laboratory	laboratory	NOUN
dpc-4042	3	148	monitoring	monitoring	NOUN
dpc-4042	3	149	citation	citation	NOUN
dpc-4042	3	150	:	:	PUNCT
dpc-4042	3	151	curtis	curtis	PROPN
dpc-4042	3	152	kl	kl	PROPN
dpc-4042	3	153	,	,	PUNCT
dpc-4042	3	154	ricardo	ricardo	PROPN
dpc-4042	3	155	jw	jw	PROPN
dpc-4042	3	156	,	,	PUNCT
dpc-4042	3	157	qiu	qiu	PROPN
dpc-4042	3	158	y	y	PROPN
dpc-4042	3	159	,	,	PUNCT
dpc-4042	3	160	et	et	PROPN
dpc-4042	3	161	al	al	PROPN
dpc-4042	3	162	.	.	PROPN
dpc-4042	4	1	retrospective	retrospective	ADJ
dpc-4042	4	2	cohort	cohort	NOUN
dpc-4042	4	3	study	study	NOUN
dpc-4042	4	4	of	of	ADP
dpc-4042	4	5	hepatic	hepatic	ADJ
dpc-4042	4	6	and	and	CCONJ
dpc-4042	4	7	hematologic	hematologic	NOUN
dpc-4042	4	8	toxicity	toxicity	NOUN
dpc-4042	4	9	in	in	ADP
dpc-4042	4	10	terbinafine	terbinafine	ADV
dpc-4042	4	11	-	-	PUNCT
dpc-4042	4	12	treated	treat	VERB
dpc-4042	4	13	onychomycosis	onychomycosis	NOUN
dpc-4042	4	14	patients	patient	NOUN
dpc-4042	4	15	with	with	ADP
dpc-4042	4	16	reduced	reduce	VERB
dpc-4042	4	17	kidney	kidney	NOUN
dpc-4042	4	18	function	function	NOUN
dpc-4042	4	19	at	at	ADP
dpc-4042	4	20	an	an	DET
dpc-4042	4	21	academic	academic	ADJ
dpc-4042	4	22	institution	institution	NOUN
dpc-4042	4	23	.	.	PUNCT
dpc-4042	5	1	dermatol	dermatol	NOUN
dpc-4042	5	2	pract	pract	PROPN
dpc-4042	5	3	concept	concept	NOUN
dpc-4042	5	4	.	.	PUNCT
dpc-4042	6	1	2024;14(2):e2024137	2024;14(2):e2024137	X
dpc-4042	6	2	.	.	PUNCT
dpc-4042	7	1	doi	doi	PROPN
dpc-4042	7	2	:	:	PUNCT
dpc-4042	7	3	https://doi.org/10.5826/dpc.1402a137	https://doi.org/10.5826/dpc.1402a137	NOUN
dpc-4042	7	4	accepted	accept	VERB
dpc-4042	7	5	:	:	PUNCT
dpc-4042	7	6	january	january	PROPN
dpc-4042	7	7	31	31	NUM
dpc-4042	7	8	,	,	PUNCT
dpc-4042	7	9	2024	2024	NUM
dpc-4042	7	10	;	;	PUNCT
dpc-4042	7	11	published	publish	VERB
dpc-4042	7	12	:	:	PUNCT
dpc-4042	8	1	april	april	PROPN
dpc-4042	8	2	2024	2024	NUM
dpc-4042	8	3	copyright	copyright	NOUN
dpc-4042	8	4	:	:	PUNCT
dpc-4042	8	5	©	©	PROPN
dpc-4042	8	6	2024	2024	NUM
dpc-4042	8	7	curtis	curtis	PROPN
dpc-4042	8	8	et	et	PROPN
dpc-4042	8	9	al	al	PROPN
dpc-4042	8	10	.	.	PUNCT
dpc-4042	9	1	this	this	PRON
dpc-4042	9	2	is	be	AUX
dpc-4042	9	3	an	an	DET
dpc-4042	9	4	open	open	ADJ
dpc-4042	9	5	-	-	PUNCT
dpc-4042	9	6	access	access	NOUN
dpc-4042	9	7	article	article	NOUN
dpc-4042	9	8	distributed	distribute	VERB
dpc-4042	9	9	under	under	ADP
dpc-4042	9	10	the	the	DET
dpc-4042	9	11	terms	term	NOUN
dpc-4042	9	12	of	of	ADP
dpc-4042	9	13	the	the	DET
dpc-4042	9	14	creative	creative	ADJ
dpc-4042	9	15	commons	common	NOUN
dpc-4042	9	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4042	9	17	license	license	NOUN
dpc-4042	9	18	(	(	PUNCT
dpc-4042	9	19	by	by	ADP
dpc-4042	9	20	-	-	PUNCT
dpc-4042	9	21	nc-4.0	nc-4.0	NOUN
dpc-4042	9	22	)	)	PUNCT
dpc-4042	9	23	,	,	PUNCT
dpc-4042	9	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4042	9	25	,	,	PUNCT
dpc-4042	9	26	which	which	PRON
dpc-4042	9	27	permits	permit	VERB
dpc-4042	9	28	unrestricted	unrestricted	ADJ
dpc-4042	9	29	noncommercial	noncommercial	ADJ
dpc-4042	9	30	use	use	NOUN
dpc-4042	9	31	,	,	PUNCT
dpc-4042	9	32	distribution	distribution	NOUN
dpc-4042	9	33	,	,	PUNCT
dpc-4042	9	34	and	and	CCONJ
dpc-4042	9	35	reproduction	reproduction	NOUN
dpc-4042	9	36	in	in	ADP
dpc-4042	9	37	any	any	DET
dpc-4042	9	38	medium	medium	NOUN
dpc-4042	9	39	,	,	PUNCT
dpc-4042	9	40	provided	provide	VERB
dpc-4042	9	41	the	the	DET
dpc-4042	9	42	original	original	ADJ
dpc-4042	9	43	authors	author	NOUN
dpc-4042	9	44	and	and	CCONJ
dpc-4042	9	45	source	source	NOUN
dpc-4042	9	46	are	be	AUX
dpc-4042	9	47	credited	credit	VERB
dpc-4042	9	48	.	.	PUNCT
dpc-4042	10	1	funding	funding	NOUN
dpc-4042	10	2	:	:	PUNCT
dpc-4042	10	3	none	none	NOUN
dpc-4042	10	4	.	.	PUNCT
dpc-4042	11	1	competing	compete	VERB
dpc-4042	11	2	interests	interest	NOUN
dpc-4042	11	3	:	:	PUNCT
dpc-4042	11	4	ms	ms	PROPN
dpc-4042	11	5	.	.	PROPN
dpc-4042	11	6	kaya	kaya	PROPN
dpc-4042	11	7	curtis	curtis	PROPN
dpc-4042	11	8	,	,	PUNCT
dpc-4042	11	9	dr	dr	PROPN
dpc-4042	11	10	.	.	PROPN
dpc-4042	11	11	jose	jose	PROPN
dpc-4042	11	12	ricardo	ricardo	PROPN
dpc-4042	11	13	,	,	PUNCT
dpc-4042	11	14	ms	ms	PROPN
dpc-4042	11	15	.	.	PROPN
dpc-4042	11	16	yuqing	yuqe	VERB
dpc-4042	11	17	qiu	qiu	PROPN
dpc-4042	11	18	,	,	PUNCT
dpc-4042	11	19	dr	dr	PROPN
dpc-4042	11	20	.	.	PROPN
dpc-4042	11	21	debra	debra	PROPN
dpc-4042	11	22	lee	lee	PROPN
dpc-4042	11	23	,	,	PUNCT
dpc-4042	11	24	dr	dr	PROPN
dpc-4042	11	25	.	.	PROPN
dpc-4042	11	26	jamie	jamie	PROPN
dpc-4042	11	27	hedrick	hedrick	PROPN
dpc-4042	11	28	,	,	PUNCT
dpc-4042	11	29	and	and	CCONJ
dpc-4042	11	30	dr	dr	PROPN
dpc-4042	11	31	.	.	PROPN
dpc-4042	11	32	henry	henry	PROPN
dpc-4042	11	33	lipner	lipner	PROPN
dpc-4042	11	34	have	have	VERB
dpc-4042	11	35	no	no	DET
dpc-4042	11	36	conflicts	conflict	NOUN
dpc-4042	11	37	of	of	ADP
dpc-4042	11	38	interest	interest	NOUN
dpc-4042	11	39	relevant	relevant	ADJ
dpc-4042	11	40	to	to	ADP
dpc-4042	11	41	the	the	DET
dpc-4042	11	42	content	content	NOUN
dpc-4042	11	43	of	of	ADP
dpc-4042	11	44	the	the	DET
dpc-4042	11	45	submission	submission	NOUN
dpc-4042	11	46	.	.	PUNCT
dpc-4042	12	1	financial	financial	ADJ
dpc-4042	12	2	disclosures	disclosure	NOUN
dpc-4042	12	3	:	:	PUNCT
dpc-4042	12	4	dr	dr	PROPN
dpc-4042	12	5	.	.	PROPN
dpc-4042	12	6	shari	shari	PROPN
dpc-4042	12	7	lipner	lipner	PROPN
dpc-4042	12	8	has	have	AUX
dpc-4042	12	9	served	serve	VERB
dpc-4042	12	10	as	as	ADP
dpc-4042	12	11	a	a	DET
dpc-4042	12	12	consult	consult	NOUN
dpc-4042	12	13	for	for	ADP
dpc-4042	12	14	orthodermatologics	orthodermatologic	NOUN
dpc-4042	12	15	,	,	PUNCT
dpc-4042	12	16	belletorus	belletorus	NOUN
dpc-4042	12	17	corporation	corporation	NOUN
dpc-4042	12	18	,	,	PUNCT
dpc-4042	12	19	eli	eli	PROPN
dpc-4042	12	20	lilly	lilly	PROPN
dpc-4042	12	21	,	,	PUNCT
dpc-4042	12	22	and	and	CCONJ
dpc-4042	12	23	moberg	moberg	PROPN
dpc-4042	12	24	pharmaceuticals	pharmaceutical	NOUN
dpc-4042	12	25	.	.	PUNCT
dpc-4042	13	1	authorship	authorship	NOUN
dpc-4042	13	2	:	:	PUNCT
dpc-4042	13	3	all	all	DET
dpc-4042	13	4	authors	author	NOUN
dpc-4042	13	5	have	have	AUX
dpc-4042	13	6	contributed	contribute	VERB
dpc-4042	13	7	significantly	significantly	ADV
dpc-4042	13	8	to	to	ADP
dpc-4042	13	9	this	this	DET
dpc-4042	13	10	publication	publication	NOUN
dpc-4042	13	11	.	.	PUNCT
dpc-4042	14	1	corresponding	correspond	VERB
dpc-4042	14	2	author	author	NOUN
dpc-4042	14	3	:	:	PUNCT
dpc-4042	14	4	shari	shari	PROPN
dpc-4042	14	5	r.	r.	PROPN
dpc-4042	14	6	lipner	lipner	PROPN
dpc-4042	14	7	md	md	PROPN
dpc-4042	14	8	,	,	PUNCT
dpc-4042	14	9	phd	phd	PROPN
dpc-4042	14	10	,	,	PUNCT
dpc-4042	14	11	1305	1305	PROPN
dpc-4042	14	12	york	york	PROPN
dpc-4042	14	13	avenue	avenue	PROPN
dpc-4042	14	14	,	,	PUNCT
dpc-4042	14	15	ny	ny	PROPN
dpc-4042	14	16	,	,	PUNCT
dpc-4042	14	17	ny	ny	PROPN
dpc-4042	14	18	10021	10021	NUM
dpc-4042	14	19	.	.	PUNCT
dpc-4042	15	1	phone	phone	NOUN
dpc-4042	15	2	:	:	PUNCT
dpc-4042	15	3	+1/646	+1/646	VERB
dpc-4042	15	4	-	-	PUNCT
dpc-4042	15	5	962	962	NUM
dpc-4042	15	6	-	-	PUNCT
dpc-4042	15	7	3376	3376	NUM
dpc-4042	15	8	fax	fax	NOUN
dpc-4042	15	9	:	:	PUNCT
dpc-4042	15	10	+1/646	+1/646	PROPN
dpc-4042	15	11	-	-	PUNCT
dpc-4042	15	12	962	962	NUM
dpc-4042	15	13	-	-	PUNCT
dpc-4042	15	14	0033	0033	NUM
dpc-4042	15	15	e	e	NOUN
dpc-4042	15	16	-	-	NOUN
dpc-4042	15	17	mail	mail	NOUN
dpc-4042	15	18	:	:	PUNCT
dpc-4042	15	19	shl9032@med.cornell.edu	shl9032@med.cornell.edu	PROPN
dpc-4042	15	20	introduction	introduction	NOUN
dpc-4042	15	21	oral	oral	ADJ
dpc-4042	15	22	terbinafine	terbinafine	NOUN
dpc-4042	15	23	,	,	PUNCT
dpc-4042	15	24	a	a	DET
dpc-4042	15	25	first	first	ADJ
dpc-4042	15	26	-	-	PUNCT
dpc-4042	15	27	line	line	NOUN
dpc-4042	15	28	onychomycosis	onychomycosis	NOUN
dpc-4042	15	29	therapy	therapy	NOUN
dpc-4042	15	30	,	,	PUNCT
dpc-4042	15	31	is	be	AUX
dpc-4042	15	32	primarily	primarily	ADV
dpc-4042	15	33	excreted	excrete	VERB
dpc-4042	15	34	renally	renally	ADV
dpc-4042	15	35	[	[	X
dpc-4042	15	36	1	1	NUM
dpc-4042	15	37	,	,	PUNCT
dpc-4042	15	38	2	2	NUM
dpc-4042	15	39	]	]	PUNCT
dpc-4042	15	40	.	.	PUNCT
dpc-4042	16	1	patients	patient	NOUN
dpc-4042	16	2	with	with	ADP
dpc-4042	16	3	renal	renal	ADJ
dpc-4042	16	4	impairment	impairment	NOUN
dpc-4042	16	5	may	may	AUX
dpc-4042	16	6	have	have	AUX
dpc-4042	16	7	increased	increase	VERB
dpc-4042	16	8	hepatic	hepatic	ADJ
dpc-4042	16	9	and	and	CCONJ
dpc-4042	16	10	hematologic	hematologic	NOUN
dpc-4042	16	11	toxicity	toxicity	NOUN
dpc-4042	16	12	risk	risk	NOUN
dpc-4042	16	13	.	.	PUNCT
dpc-4042	17	1	onychomycosis	onychomycosis	NOUN
dpc-4042	17	2	was	be	AUX
dpc-4042	17	3	~2x	~2x	ADV
dpc-4042	17	4	more	more	ADV
dpc-4042	17	5	common	common	ADJ
dpc-4042	17	6	in	in	ADP
dpc-4042	17	7	hemodialysis	hemodialysis	NOUN
dpc-4042	17	8	and	and	CCONJ
dpc-4042	17	9	kidney	kidney	NOUN
dpc-4042	17	10	transplant	transplant	NOUN
dpc-4042	17	11	patients	patient	NOUN
dpc-4042	17	12	vs.	vs.	ADP
dpc-4042	17	13	non	non	ADJ
dpc-4042	17	14	-	-	ADJ
dpc-4042	17	15	renal	renal	ADJ
dpc-4042	17	16	disease	disease	NOUN
dpc-4042	17	17	controls	control	VERB
dpc-4042	17	18	in	in	ADP
dpc-4042	17	19	a	a	DET
dpc-4042	17	20	prospective	prospective	ADJ
dpc-4042	17	21	study	study	NOUN
dpc-4042	17	22	(	(	PUNCT
dpc-4042	17	23	n=510	n=510	NOUN
dpc-4042	17	24	,	,	PUNCT
dpc-4042	17	25	p=0.03	p=0.03	ADJ
dpc-4042	17	26	)	)	PUNCT
dpc-4042	18	1	[	[	X
dpc-4042	18	2	3	3	NUM
dpc-4042	18	3	]	]	PUNCT
dpc-4042	18	4	.	.	PUNCT
dpc-4042	19	1	therefore	therefore	ADV
dpc-4042	19	2	,	,	PUNCT
dpc-4042	19	3	we	we	PRON
dpc-4042	19	4	aimed	aim	VERB
dpc-4042	19	5	to	to	PART
dpc-4042	19	6	evaluate	evaluate	VERB
dpc-4042	19	7	the	the	DET
dpc-4042	19	8	association	association	NOUN
dpc-4042	19	9	between	between	ADP
dpc-4042	19	10	kidney	kidney	NOUN
dpc-4042	19	11	function	function	NOUN
dpc-4042	19	12	and	and	CCONJ
dpc-4042	19	13	laboratory	laboratory	NOUN
dpc-4042	19	14	test	test	NOUN
dpc-4042	19	15	abnormality	abnormality	NOUN
dpc-4042	19	16	rates	rate	NOUN
dpc-4042	19	17	in	in	ADP
dpc-4042	19	18	terbinafine	terbinafine	ADV
dpc-4042	19	19	-	-	PUNCT
dpc-4042	19	20	treated	treat	VERB
dpc-4042	19	21	onychomycosis	onychomycosis	NOUN
dpc-4042	19	22	patients	patient	NOUN
dpc-4042	19	23	.	.	PUNCT
dpc-4042	20	1	case	case	NOUN
dpc-4042	20	2	presentation	presentation	NOUN
dpc-4042	20	3	aspartate	aspartate	NOUN
dpc-4042	20	4	aminotransferase	aminotransferase	NOUN
dpc-4042	20	5	(	(	PUNCT
dpc-4042	20	6	ast	ast	PROPN
dpc-4042	20	7	)	)	PUNCT
dpc-4042	20	8	,	,	PUNCT
dpc-4042	20	9	alanine	alanine	NOUN
dpc-4042	20	10	aminotransferase	aminotransferase	PROPN
dpc-4042	20	11	(	(	PUNCT
dpc-4042	20	12	alt	alt	ADJ
dpc-4042	20	13	)	)	PUNCT
dpc-4042	20	14	,	,	PUNCT
dpc-4042	20	15	and	and	CCONJ
dpc-4042	20	16	complete	complete	ADJ
dpc-4042	20	17	blood	blood	NOUN
dpc-4042	20	18	count	count	NOUN
dpc-4042	20	19	(	(	PUNCT
dpc-4042	20	20	cbc	cbc	NOUN
dpc-4042	20	21	)	)	PUNCT
dpc-4042	20	22	tests	test	NOUN
dpc-4042	20	23	of	of	ADP
dpc-4042	20	24	terbinafine	terbinafine	ADV
dpc-4042	20	25	-	-	PUNCT
dpc-4042	20	26	treated	treat	VERB
dpc-4042	20	27	adults	adult	NOUN
dpc-4042	20	28	with	with	ADP
dpc-4042	20	29	onychomycosis	onychomycosis	NOUN
dpc-4042	20	30	(	(	PUNCT
dpc-4042	20	31	2000	2000	NUM
dpc-4042	20	32	-	-	SYM
dpc-4042	20	33	2021	2021	NUM
dpc-4042	20	34	)	)	PUNCT
dpc-4042	20	35	≤3	≤3	ADJ
dpc-4042	20	36	months	month	NOUN
dpc-4042	20	37	before	before	ADV
dpc-4042	20	38	,	,	PUNCT
dpc-4042	20	39	during	during	ADP
dpc-4042	20	40	,	,	PUNCT
dpc-4042	20	41	and	and	CCONJ
dpc-4042	20	42	≤3	≤3	ADJ
dpc-4042	20	43	months	month	NOUN
dpc-4042	20	44	after	after	SCONJ
dpc-4042	20	45	treatment	treatment	NOUN
dpc-4042	20	46	were	be	AUX
dpc-4042	20	47	collected	collect	VERB
dpc-4042	20	48	(	(	PUNCT
dpc-4042	20	49	supplemental	supplemental	ADJ
dpc-4042	20	50	methods	method	NOUN
dpc-4042	20	51	)	)	PUNCT
dpc-4042	20	52	.	.	PUNCT
dpc-4042	21	1	of	of	ADP
dpc-4042	21	2	2,195	2,195	NUM
dpc-4042	21	3	records	record	NOUN
dpc-4042	21	4	,	,	PUNCT
dpc-4042	21	5	734	734	NUM
dpc-4042	21	6	patients	patient	NOUN
dpc-4042	21	7	were	be	AUX
dpc-4042	21	8	included	include	VERB
dpc-4042	21	9	,	,	PUNCT
dpc-4042	21	10	with	with	ADP
dpc-4042	21	11	an	an	DET
dpc-4042	21	12	average	average	ADJ
dpc-4042	21	13	age	age	NOUN
dpc-4042	21	14	of	of	ADP
dpc-4042	21	15	55.2	55.2	NUM
dpc-4042	21	16	years	year	NOUN
dpc-4042	21	17	(	(	PUNCT
dpc-4042	21	18	supplemental	supplemental	ADJ
dpc-4042	21	19	table	table	NOUN
dpc-4042	21	20	1	1	NUM
dpc-4042	21	21	)	)	PUNCT
dpc-4042	21	22	.	.	PUNCT
dpc-4042	22	1	two	two	NUM
dpc-4042	22	2	hundred	hundred	NUM
dpc-4042	22	3	eighty	eighty	NUM
dpc-4042	22	4	-	-	PUNCT
dpc-4042	22	5	five	five	NUM
dpc-4042	22	6	patients	patient	NOUN
dpc-4042	22	7	had	have	VERB
dpc-4042	22	8	abnormal	abnormal	ADJ
dpc-4042	22	9	renal	renal	ADJ
dpc-4042	22	10	function	function	NOUN
dpc-4042	22	11	,	,	PUNCT
dpc-4042	22	12	and	and	CCONJ
dpc-4042	22	13	proportion	proportion	NOUN
dpc-4042	22	14	of	of	ADP
dpc-4042	22	15	abnormal	abnormal	ADJ
dpc-4042	22	16	ast	ast	NOUN
dpc-4042	22	17	,	,	PUNCT
dpc-4042	22	18	alt	alt	ADJ
dpc-4042	22	19	,	,	PUNCT
dpc-4042	22	20	and	and	CCONJ
dpc-4042	22	21	cbc	cbc	NOUN
dpc-4042	22	22	values	value	NOUN
dpc-4042	22	23	2	2	NUM
dpc-4042	22	24	research	research	NOUN
dpc-4042	22	25	letter	letter	NOUN
dpc-4042	23	1	|	|	ADV
dpc-4042	23	2	dermatol	dermatol	ADJ
dpc-4042	23	3	pract	pract	NOUN
dpc-4042	23	4	concept	concept	NOUN
dpc-4042	23	5	.	.	PUNCT
dpc-4042	24	1	2024;14(2):e2024137	2024;14(2):e2024137	NUM
dpc-4042	24	2	were	be	AUX
dpc-4042	24	3	similar	similar	ADJ
dpc-4042	24	4	during	during	ADP
dpc-4042	24	5	and	and	CCONJ
dpc-4042	24	6	post	post	ADJ
dpc-4042	24	7	-	-	ADJ
dpc-4042	24	8	terbinafine	terbinafine	ADJ
dpc-4042	24	9	treatment	treatment	NOUN
dpc-4042	24	10	vs.	vs.	X
dpc-4042	24	11	pre	pre	X
dpc-4042	24	12	treatment	treatment	NOUN
dpc-4042	24	13	(	(	PUNCT
dpc-4042	24	14	supplemental	supplemental	ADJ
dpc-4042	24	15	table	table	NOUN
dpc-4042	24	16	2	2	NUM
dpc-4042	24	17	)	)	PUNCT
dpc-4042	24	18	.	.	PUNCT
dpc-4042	25	1	after	after	ADP
dpc-4042	25	2	matching	match	VERB
dpc-4042	25	3	for	for	ADP
dpc-4042	25	4	age	age	NOUN
dpc-4042	25	5	,	,	PUNCT
dpc-4042	25	6	sex	sex	NOUN
dpc-4042	25	7	,	,	PUNCT
dpc-4042	25	8	weight	weight	NOUN
dpc-4042	25	9	,	,	PUNCT
dpc-4042	25	10	hepatic	hepatic	ADJ
dpc-4042	25	11	/	/	SYM
dpc-4042	25	12	hematologic	hematologic	NOUN
dpc-4042	25	13	disease	disease	NOUN
dpc-4042	25	14	,	,	PUNCT
dpc-4042	25	15	terbinafine	terbinafine	ADV
dpc-4042	25	16	-	-	PUNCT
dpc-4042	25	17	treated	treat	VERB
dpc-4042	25	18	stage	stage	NOUN
dpc-4042	25	19	2	2	NUM
dpc-4042	25	20	chronic	chronic	ADJ
dpc-4042	25	21	renal	renal	ADJ
dpc-4042	25	22	insufficiency	insufficiency	NOUN
dpc-4042	25	23	(	(	PUNCT
dpc-4042	25	24	cri	cri	PROPN
dpc-4042	25	25	)	)	PUNCT
dpc-4042	25	26	vs.	vs.	ADP
dpc-4042	25	27	stage	stage	NOUN
dpc-4042	25	28	1	1	NUM
dpc-4042	25	29	cri	cri	NOUN
dpc-4042	25	30	and	and	CCONJ
dpc-4042	25	31	stage	stage	NOUN
dpc-4042	25	32	3	3	NUM
dpc-4042	25	33	cri	cri	NOUN
dpc-4042	25	34	vs.	vs.	ADP
dpc-4042	25	35	stage	stage	NOUN
dpc-4042	25	36	1	1	NUM
dpc-4042	25	37	cri	cri	PROPN
dpc-4042	25	38	patients	patient	NOUN
dpc-4042	25	39	had	have	VERB
dpc-4042	25	40	similar	similar	ADJ
dpc-4042	25	41	laboratory	laboratory	NOUN
dpc-4042	25	42	abnormality	abnormality	NOUN
dpc-4042	25	43	risk	risk	NOUN
dpc-4042	25	44	during	during	ADP
dpc-4042	25	45	and	and	CCONJ
dpc-4042	25	46	post	post	ADJ
dpc-4042	25	47	-	-	ADJ
dpc-4042	25	48	treatment	treatment	NOUN
dpc-4042	25	49	vs.	vs.	X
dpc-4042	25	50	baseline	baseline	NOUN
dpc-4042	25	51	(	(	PUNCT
dpc-4042	25	52	table	table	NOUN
dpc-4042	25	53	1	1	NUM
dpc-4042	25	54	)	)	PUNCT
dpc-4042	25	55	.	.	PUNCT
dpc-4042	26	1	stage	stage	NOUN
dpc-4042	26	2	1	1	NUM
dpc-4042	26	3	cri	cri	PROPN
dpc-4042	26	4	patients	patient	NOUN
dpc-4042	26	5	had	have	AUX
dpc-4042	26	6	mean	mean	VERB
dpc-4042	26	7	0.02mg	0.02mg	X
dpc-4042	26	8	/	/	SYM
dpc-4042	26	9	dl	dl	PROPN
dpc-4042	26	10	serum	serum	PROPN
dpc-4042	26	11	creatinine	creatinine	PROPN
dpc-4042	26	12	change	change	NOUN
dpc-4042	26	13	from	from	ADP
dpc-4042	26	14	baseline	baseline	NOUN
dpc-4042	26	15	to	to	ADP
dpc-4042	26	16	during	during	ADP
dpc-4042	26	17	treatment	treatment	NOUN
dpc-4042	26	18	and	and	CCONJ
dpc-4042	26	19	baseline	baseline	VERB
dpc-4042	26	20	to	to	ADP
dpc-4042	26	21	post	post	ADJ
dpc-4042	26	22	-	-	NOUN
dpc-4042	26	23	treatment	treatment	NOUN
dpc-4042	26	24	(	(	PUNCT
dpc-4042	26	25	both	both	DET
dpc-4042	26	26	95	95	NUM
dpc-4042	26	27	%	%	NOUN
dpc-4042	26	28	ci	ci	NOUN
dpc-4042	26	29	:	:	PUNCT
dpc-4042	26	30	0.01–0.04	0.01–0.04	NUM
dpc-4042	26	31	,	,	PUNCT
dpc-4042	26	32	p=0.002	p=0.002	NOUN
dpc-4042	26	33	,	,	PUNCT
dpc-4042	26	34	p=0.005	p=0.005	X
dpc-4042	26	35	,	,	PUNCT
dpc-4042	26	36	respectively	respectively	ADV
dpc-4042	26	37	)	)	PUNCT
dpc-4042	26	38	.	.	PUNCT
dpc-4042	27	1	mean	mean	ADJ
dpc-4042	27	2	creatinine	creatinine	NOUN
dpc-4042	27	3	was	be	AUX
dpc-4042	27	4	stable	stable	ADJ
dpc-4042	27	5	from	from	ADP
dpc-4042	27	6	baseline	baseline	NOUN
dpc-4042	27	7	to	to	ADP
dpc-4042	27	8	during	during	ADP
dpc-4042	27	9	and	and	CCONJ
dpc-4042	27	10	post	post	ADJ
dpc-4042	27	11	-	-	NOUN
dpc-4042	27	12	treatment	treatment	NOUN
dpc-4042	27	13	for	for	ADP
dpc-4042	27	14	stages	stage	NOUN
dpc-4042	27	15	2	2	NUM
dpc-4042	27	16	and	and	CCONJ
dpc-4042	27	17	3	3	NUM
dpc-4042	27	18	cri	cri	X
dpc-4042	27	19	(	(	PUNCT
dpc-4042	27	20	supplemental	supplemental	ADJ
dpc-4042	27	21	table	table	NOUN
dpc-4042	27	22	3	3	NUM
dpc-4042	27	23	)	)	PUNCT
dpc-4042	27	24	.	.	PUNCT
dpc-4042	28	1	discussion	discussion	NOUN
dpc-4042	28	2	our	our	PRON
dpc-4042	28	3	study	study	NOUN
dpc-4042	28	4	suggests	suggest	VERB
dpc-4042	28	5	that	that	SCONJ
dpc-4042	28	6	terbinafine	terbinafine	NOUN
dpc-4042	28	7	-	-	PUNCT
dpc-4042	28	8	treated	treat	VERB
dpc-4042	28	9	onychomycosis	onychomycosis	NOUN
dpc-4042	28	10	patients	patient	NOUN
dpc-4042	28	11	with	with	ADP
dpc-4042	28	12	stages	stage	NOUN
dpc-4042	28	13	2	2	NUM
dpc-4042	28	14	or	or	CCONJ
dpc-4042	28	15	3	3	NUM
dpc-4042	28	16	cri	cri	NOUN
dpc-4042	28	17	are	be	AUX
dpc-4042	28	18	not	not	PART
dpc-4042	28	19	at	at	ADP
dpc-4042	28	20	increased	increase	VERB
dpc-4042	28	21	risk	risk	NOUN
dpc-4042	28	22	of	of	ADP
dpc-4042	28	23	developing	develop	VERB
dpc-4042	28	24	laboratory	laboratory	NOUN
dpc-4042	28	25	abnormalities	abnormality	NOUN
dpc-4042	28	26	vs.	vs.	ADP
dpc-4042	28	27	patients	patient	NOUN
dpc-4042	28	28	with	with	ADP
dpc-4042	28	29	normal	normal	ADJ
dpc-4042	28	30	kidney	kidney	NOUN
dpc-4042	28	31	function	function	NOUN
dpc-4042	28	32	(	(	PUNCT
dpc-4042	28	33	stage	stage	NOUN
dpc-4042	28	34	1	1	NUM
dpc-4042	28	35	cri	cri	PROPN
dpc-4042	28	36	)	)	PUNCT
dpc-4042	28	37	.	.	PUNCT
dpc-4042	29	1	creatinine	creatinine	PROPN
dpc-4042	29	2	increased	increase	VERB
dpc-4042	29	3	in	in	ADP
dpc-4042	29	4	stage	stage	NOUN
dpc-4042	29	5	1	1	NUM
dpc-4042	29	6	cri	cri	PROPN
dpc-4042	29	7	terbinafine	terbinafine	ADV
dpc-4042	29	8	-	-	PUNCT
dpc-4042	29	9	treated	treat	VERB
dpc-4042	29	10	patients	patient	NOUN
dpc-4042	29	11	,	,	PUNCT
dpc-4042	29	12	which	which	PRON
dpc-4042	29	13	may	may	AUX
dpc-4042	29	14	be	be	AUX
dpc-4042	29	15	due	due	ADJ
dpc-4042	29	16	to	to	ADP
dpc-4042	29	17	laboratory	laboratory	NOUN
dpc-4042	29	18	variations	variation	NOUN
dpc-4042	29	19	and	and	CCONJ
dpc-4042	29	20	was	be	AUX
dpc-4042	29	21	clinically	clinically	ADV
dpc-4042	29	22	insignificant	insignificant	ADJ
dpc-4042	29	23	.	.	PUNCT
dpc-4042	30	1	we	we	PRON
dpc-4042	30	2	found	find	VERB
dpc-4042	30	3	no	no	DET
dpc-4042	30	4	difference	difference	NOUN
dpc-4042	30	5	between	between	ADP
dpc-4042	30	6	baseline	baseline	NOUN
dpc-4042	30	7	and	and	CCONJ
dpc-4042	30	8	monitoring	monitor	VERB
dpc-4042	30	9	hepatic	hepatic	ADJ
dpc-4042	30	10	and	and	CCONJ
dpc-4042	30	11	hematologic	hematologic	NOUN
dpc-4042	30	12	laboratory	laboratory	NOUN
dpc-4042	30	13	values	value	NOUN
dpc-4042	30	14	,	,	PUNCT
dpc-4042	30	15	similar	similar	ADJ
dpc-4042	30	16	to	to	ADP
dpc-4042	30	17	a	a	DET
dpc-4042	30	18	retrospective	retrospective	ADJ
dpc-4042	30	19	cohort	cohort	NOUN
dpc-4042	30	20	study	study	NOUN
dpc-4042	30	21	[	[	X
dpc-4042	30	22	4	4	X
dpc-4042	30	23	]	]	PUNCT
dpc-4042	30	24	of	of	ADP
dpc-4042	30	25	4,309	4,309	NUM
dpc-4042	30	26	terbinafine	terbinafine	ADJ
dpc-4042	30	27	courses	course	NOUN
dpc-4042	30	28	for	for	ADP
dpc-4042	30	29	dermatophyte	dermatophyte	NOUN
dpc-4042	30	30	infection	infection	NOUN
dpc-4042	30	31	(	(	PUNCT
dpc-4042	30	32	majority	majority	NOUN
dpc-4042	30	33	onychomycosis	onychomycosis	NOUN
dpc-4042	30	34	)	)	PUNCT
dpc-4042	30	35	,	,	PUNCT
dpc-4042	30	36	where	where	SCONJ
dpc-4042	30	37	transaminitis	transaminitis	NOUN
dpc-4042	30	38	,	,	PUNCT
dpc-4042	30	39	anemia	anemia	NOUN
dpc-4042	30	40	,	,	PUNCT
dpc-4042	30	41	lymphopenia	lymphopenia	NOUN
dpc-4042	30	42	,	,	PUNCT
dpc-4042	30	43	and	and	CCONJ
dpc-4042	30	44	neutropenia	neutropenia	NOUN
dpc-4042	30	45	rates	rate	NOUN
dpc-4042	30	46	were	be	AUX
dpc-4042	30	47	low	low	ADJ
dpc-4042	30	48	and	and	CCONJ
dpc-4042	30	49	comparable	comparable	ADJ
dpc-4042	30	50	to	to	AUX
dpc-4042	30	51	baseline	baseline	VERB
dpc-4042	30	52	.	.	PUNCT
dpc-4042	31	1	in	in	ADP
dpc-4042	31	2	a	a	DET
dpc-4042	31	3	population	population	NOUN
dpc-4042	31	4	-	-	PUNCT
dpc-4042	31	5	based	base	VERB
dpc-4042	31	6	study	study	NOUN
dpc-4042	31	7	[	[	X
dpc-4042	31	8	5	5	NUM
dpc-4042	31	9	]	]	PUNCT
dpc-4042	31	10	of	of	ADP
dpc-4042	31	11	12,376	12,376	NUM
dpc-4042	31	12	patients	patient	NOUN
dpc-4042	31	13	,	,	PUNCT
dpc-4042	31	14	incidence	incidence	NOUN
dpc-4042	31	15	of	of	ADP
dpc-4042	31	16	terbinafineinduced	terbinafineinduce	VERB
dpc-4042	31	17	liver	liver	NOUN
dpc-4042	31	18	injury	injury	NOUN
dpc-4042	31	19	was	be	AUX
dpc-4042	31	20	1.6/10,000	1.6/10,000	ADJ
dpc-4042	31	21	persons	person	NOUN
dpc-4042	31	22	.	.	PUNCT
dpc-4042	32	1	since	since	SCONJ
dpc-4042	32	2	terbinafine	terbinafine	NOUN
dpc-4042	32	3	is	be	AUX
dpc-4042	32	4	primarily	primarily	ADV
dpc-4042	32	5	excreted	excrete	VERB
dpc-4042	32	6	in	in	ADP
dpc-4042	32	7	the	the	DET
dpc-4042	32	8	urine	urine	NOUN
dpc-4042	32	9	(	(	PUNCT
dpc-4042	32	10	80	80	NUM
dpc-4042	32	11	%	%	NOUN
dpc-4042	32	12	)	)	PUNCT
dpc-4042	32	13	,	,	PUNCT
dpc-4042	32	14	with	with	SCONJ
dpc-4042	32	15	creatinine	creatinine	NOUN
dpc-4042	32	16	clearance	clearance	NOUN
dpc-4042	32	17	decreased	decrease	VERB
dpc-4042	32	18	by	by	ADP
dpc-4042	32	19	50	50	NUM
dpc-4042	32	20	%	%	NOUN
dpc-4042	32	21	in	in	ADP
dpc-4042	32	22	patients	patient	NOUN
dpc-4042	32	23	with	with	ADP
dpc-4042	32	24	<	<	X
dpc-4042	32	25	50	50	NUM
dpc-4042	32	26	ml	ml	NOUN
dpc-4042	32	27	/	/	SYM
dpc-4042	32	28	min	min	NOUN
dpc-4042	33	1	[	[	X
dpc-4042	33	2	1	1	NUM
dpc-4042	33	3	]	]	PUNCT
dpc-4042	33	4	,	,	PUNCT
dpc-4042	33	5	reducing	reduce	VERB
dpc-4042	33	6	daily	daily	ADJ
dpc-4042	33	7	terbinafine	terbinafine	ADJ
dpc-4042	33	8	dosage	dosage	NOUN
dpc-4042	33	9	by	by	ADP
dpc-4042	33	10	half	half	NOUN
dpc-4042	33	11	has	have	AUX
dpc-4042	33	12	been	be	AUX
dpc-4042	33	13	suggested	suggest	VERB
dpc-4042	33	14	for	for	ADP
dpc-4042	33	15	patients	patient	NOUN
dpc-4042	33	16	with	with	ADP
dpc-4042	33	17	reduced	reduced	ADJ
dpc-4042	33	18	renal	renal	ADJ
dpc-4042	33	19	function	function	NOUN
dpc-4042	33	20	[	[	X
dpc-4042	33	21	2	2	NUM
dpc-4042	33	22	]	]	PUNCT
dpc-4042	33	23	.	.	PUNCT
dpc-4042	34	1	however	however	ADV
dpc-4042	34	2	,	,	PUNCT
dpc-4042	34	3	the	the	DET
dpc-4042	34	4	package	package	NOUN
dpc-4042	34	5	insert	insert	NOUN
dpc-4042	34	6	does	do	AUX
dpc-4042	34	7	not	not	PART
dpc-4042	34	8	mention	mention	VERB
dpc-4042	34	9	dose	dose	NOUN
dpc-4042	34	10	reduction	reduction	NOUN
dpc-4042	34	11	table	table	NOUN
dpc-4042	34	12	1	1	NUM
dpc-4042	34	13	.	.	PUNCT
dpc-4042	34	14	risk	risk	NOUN
dpc-4042	34	15	of	of	ADP
dpc-4042	34	16	developing	develop	VERB
dpc-4042	34	17	laboratory	laboratory	NOUN
dpc-4042	34	18	abnormalities	abnormality	NOUN
dpc-4042	34	19	in	in	ADP
dpc-4042	34	20	terbinafine	terbinafine	ADV
dpc-4042	34	21	-	-	PUNCT
dpc-4042	34	22	treated	treat	VERB
dpc-4042	34	23	patients	patient	NOUN
dpc-4042	34	24	with	with	ADP
dpc-4042	34	25	stage	stage	NOUN
dpc-4042	34	26	2/	2/	NUM
dpc-4042	34	27	stage	stage	NOUN
dpc-4042	34	28	3	3	NUM
dpc-4042	34	29	cri	cri	PROPN
dpc-4042	34	30	compared	compare	VERB
dpc-4042	34	31	to	to	ADP
dpc-4042	34	32	patients	patient	NOUN
dpc-4042	34	33	with	with	ADP
dpc-4042	34	34	stage	stage	NOUN
dpc-4042	34	35	1	1	NUM
dpc-4042	34	36	cri	cri	PROPN
dpc-4042	34	37	*	*	PROPN
dpc-4042	34	38	stage	stage	NOUN
dpc-4042	34	39	2	2	NUM
dpc-4042	34	40	cri	cri	PROPN
dpc-4042	34	41	compared	compare	VERB
dpc-4042	34	42	to	to	ADP
dpc-4042	34	43	stage	stage	NOUN
dpc-4042	34	44	1	1	NUM
dpc-4042	34	45	cri	cri	PROPN
dpc-4042	34	46	outcome	outcome	NOUN
dpc-4042	34	47	variable	variable	NOUN
dpc-4042	34	48	  	  	SPACE
dpc-4042	34	49	odds	odd	NOUN
dpc-4042	34	50	ratio	ratio	NOUN
dpc-4042	34	51	  	  	SPACE
dpc-4042	34	52	95	95	NUM
dpc-4042	34	53	%	%	NOUN
dpc-4042	34	54	confidence	confidence	NOUN
dpc-4042	34	55	interval	interval	NOUN
dpc-4042	34	56	  	  	SPACE
dpc-4042	34	57	p	p	NOUN
dpc-4042	34	58	value	value	NOUN
dpc-4042	34	59	  	  	SPACE
dpc-4042	34	60	abnormal	abnormal	ADJ
dpc-4042	34	61	ast	ast	NOUN
dpc-4042	34	62	results	result	VERB
dpc-4042	34	63	post	post	ADJ
dpc-4042	34	64	-	-	ADJ
dpc-4042	34	65	treatment	treatment	ADJ
dpc-4042	34	66	  	  	SPACE
dpc-4042	34	67	1.21	1.21	NUM
dpc-4042	34	68	0–785.34	0–785.34	NUM
dpc-4042	34	69	0.131	0.131	NUM
dpc-4042	34	70	abnormal	abnormal	ADJ
dpc-4042	34	71	ast	ast	NOUN
dpc-4042	34	72	results	result	NOUN
dpc-4042	34	73	during	during	ADP
dpc-4042	34	74	treatment	treatment	NOUN
dpc-4042	34	75	  	  	SPACE
dpc-4042	34	76	0.85	0.85	NUM
dpc-4042	34	77	0.36–2.02	0.36–2.02	NUM
dpc-4042	34	78	0.717	0.717	NUM
dpc-4042	34	79	abnormal	abnormal	ADJ
dpc-4042	34	80	alt	alt	NOUN
dpc-4042	34	81	results	result	VERB
dpc-4042	34	82	post	post	ADJ
dpc-4042	34	83	-	-	ADJ
dpc-4042	34	84	treatment	treatment	ADJ
dpc-4042	34	85	  	  	SPACE
dpc-4042	34	86	0.29	0.29	NUM
dpc-4042	34	87	0.06–1.48	0.06–1.48	NUM
dpc-4042	34	88	0.137	0.137	NUM
dpc-4042	34	89	abnormal	abnormal	ADJ
dpc-4042	34	90	alt	alt	NOUN
dpc-4042	34	91	results	result	NOUN
dpc-4042	34	92	during	during	ADP
dpc-4042	34	93	treatment	treatment	NOUN
dpc-4042	34	94	   	   	SPACE
dpc-4042	34	95	0.98	0.98	NUM
dpc-4042	34	96	0–644.37	0–644.37	NUM
dpc-4042	34	97	0.994	0.994	NUM
dpc-4042	34	98	abnormal	abnormal	ADJ
dpc-4042	34	99	cbc	cbc	NOUN
dpc-4042	34	100	results	result	VERB
dpc-4042	34	101	post	post	ADJ
dpc-4042	34	102	-	-	ADJ
dpc-4042	34	103	treatment	treatment	ADJ
dpc-4042	34	104	  	  	SPACE
dpc-4042	34	105	1.01	1.01	NUM
dpc-4042	34	106	0.4–2.55	0.4–2.55	NUM
dpc-4042	34	107	0.981	0.981	NUM
dpc-4042	34	108	abnormal	abnormal	ADJ
dpc-4042	34	109	cbc	cbc	NOUN
dpc-4042	34	110	results	result	NOUN
dpc-4042	34	111	during	during	ADP
dpc-4042	34	112	treatment	treatment	NOUN
dpc-4042	34	113	  	  	SPACE
dpc-4042	34	114	1.49	1.49	NUM
dpc-4042	34	115	0.67–3.3	0.67–3.3	NUM
dpc-4042	34	116	0.329	0.329	NUM
dpc-4042	34	117	stage	stage	NOUN
dpc-4042	34	118	3	3	NUM
dpc-4042	34	119	cri	cri	PROPN
dpc-4042	34	120	compared	compare	VERB
dpc-4042	34	121	to	to	ADP
dpc-4042	34	122	stage	stage	NOUN
dpc-4042	34	123	1	1	NUM
dpc-4042	34	124	cri	cri	PROPN
dpc-4042	34	125	outcome	outcome	NOUN
dpc-4042	34	126	variable	variable	NOUN
dpc-4042	34	127	  	  	SPACE
dpc-4042	34	128	odds	odd	NOUN
dpc-4042	34	129	ratio	ratio	NOUN
dpc-4042	34	130	  	  	SPACE
dpc-4042	34	131	95	95	NUM
dpc-4042	34	132	%	%	NOUN
dpc-4042	34	133	confidence	confidence	NOUN
dpc-4042	34	134	interval	interval	NOUN
dpc-4042	34	135	  	  	SPACE
dpc-4042	34	136	p	p	NOUN
dpc-4042	34	137	value	value	NOUN
dpc-4042	34	138	  	  	SPACE
dpc-4042	34	139	abnormal	abnormal	ADJ
dpc-4042	34	140	ast	ast	NOUN
dpc-4042	34	141	results	result	VERB
dpc-4042	34	142	post	post	ADJ
dpc-4042	34	143	-	-	NOUN
dpc-4042	34	144	treatment	treatment	ADJ
dpc-4042	34	145	*	*	PUNCT
dpc-4042	34	146	*	*	PUNCT
dpc-4042	34	147	---abnormal	---abnormal	ADJ
dpc-4042	34	148	ast	ast	NOUN
dpc-4042	34	149	results	result	NOUN
dpc-4042	34	150	during	during	ADP
dpc-4042	34	151	treatment	treatment	NOUN
dpc-4042	34	152	  	  	SPACE
dpc-4042	34	153	0.9	0.9	NUM
dpc-4042	34	154	0.11–7.17	0.11–7.17	NOUN
dpc-4042	34	155	0.924	0.924	NUM
dpc-4042	34	156	abnormal	abnormal	ADJ
dpc-4042	34	157	alt	alt	NOUN
dpc-4042	34	158	results	result	VERB
dpc-4042	34	159	post	post	ADJ
dpc-4042	34	160	-	-	NOUN
dpc-4042	34	161	treatment	treatment	ADJ
dpc-4042	34	162	*	*	PUNCT
dpc-4042	34	163	*	*	NOUN
dpc-4042	34	164	  	  	SPACE
dpc-4042	34	165	---abnormal	---abnormal	ADJ
dpc-4042	34	166	alt	alt	VERB
dpc-4042	34	167	results	result	NOUN
dpc-4042	34	168	during	during	ADP
dpc-4042	34	169	treatment	treatment	NOUN
dpc-4042	34	170	*	*	NOUN
dpc-4042	34	171	*	*	PUNCT
dpc-4042	34	172	--	--	PUNCT
dpc-4042	34	173	  	  	SPACE
dpc-4042	34	174	--abnormal	--abnormal	PUNCT
dpc-4042	34	175	cbc	cbc	PROPN
dpc-4042	34	176	results	result	VERB
dpc-4042	34	177	post	post	ADJ
dpc-4042	34	178	-	-	ADJ
dpc-4042	34	179	treatment	treatment	ADJ
dpc-4042	34	180	  	  	SPACE
dpc-4042	34	181	3.66	3.66	NUM
dpc-4042	34	182	0.5–26.79	0.5–26.79	NOUN
dpc-4042	34	183	0.202	0.202	NUM
dpc-4042	34	184	abnormal	abnormal	ADJ
dpc-4042	34	185	cbc	cbc	NOUN
dpc-4042	34	186	results	result	NOUN
dpc-4042	34	187	during	during	ADP
dpc-4042	34	188	treatment	treatment	NOUN
dpc-4042	34	189	  	  	SPACE
dpc-4042	34	190	3.35	3.35	NUM
dpc-4042	34	191	0.54–20.82	0.54–20.82	NUM
dpc-4042	34	192	0.194	0.194	NUM
dpc-4042	34	193	*	*	PUNCT
dpc-4042	34	194	after	after	ADP
dpc-4042	34	195	matching	match	VERB
dpc-4042	34	196	and	and	CCONJ
dpc-4042	34	197	adjusting	adjust	VERB
dpc-4042	34	198	for	for	ADP
dpc-4042	34	199	covariates	covariate	NOUN
dpc-4042	34	200	,	,	PUNCT
dpc-4042	34	201	including	include	VERB
dpc-4042	34	202	age	age	NOUN
dpc-4042	34	203	,	,	PUNCT
dpc-4042	34	204	sex	sex	NOUN
dpc-4042	34	205	,	,	PUNCT
dpc-4042	34	206	weight	weight	NOUN
dpc-4042	34	207	,	,	PUNCT
dpc-4042	34	208	presence	presence	NOUN
dpc-4042	34	209	of	of	ADP
dpc-4042	34	210	hepatic	hepatic	ADJ
dpc-4042	34	211	/	/	SYM
dpc-4042	34	212	hematologic	hematologic	NOUN
dpc-4042	34	213	disease	disease	NOUN
dpc-4042	34	214	,	,	PUNCT
dpc-4042	34	215	and	and	CCONJ
dpc-4042	34	216	baseline	baseline	VERB
dpc-4042	34	217	ast	ast	PROPN
dpc-4042	34	218	,	,	PUNCT
dpc-4042	34	219	alt	alt	ADJ
dpc-4042	34	220	,	,	PUNCT
dpc-4042	34	221	cbc	cbc	NOUN
dpc-4042	34	222	laboratory	laboratory	NOUN
dpc-4042	34	223	tests	test	NOUN
dpc-4042	34	224	.	.	PUNCT
dpc-4042	35	1	*	*	PUNCT
dpc-4042	35	2	*	*	NOUN
dpc-4042	35	3	odds	odd	NOUN
dpc-4042	35	4	ratios	ratio	NOUN
dpc-4042	35	5	could	could	AUX
dpc-4042	35	6	not	not	PART
dpc-4042	35	7	be	be	AUX
dpc-4042	35	8	calculated	calculate	VERB
dpc-4042	35	9	due	due	ADJ
dpc-4042	35	10	to	to	ADP
dpc-4042	35	11	lack	lack	NOUN
dpc-4042	35	12	of	of	ADP
dpc-4042	35	13	laboratory	laboratory	NOUN
dpc-4042	35	14	values	value	NOUN
dpc-4042	35	15	in	in	ADP
dpc-4042	35	16	stage	stage	NOUN
dpc-4042	35	17	1	1	NUM
dpc-4042	35	18	or	or	CCONJ
dpc-4042	35	19	stage	stage	VERB
dpc-4042	35	20	3	3	NUM
dpc-4042	35	21	groups	group	NOUN
dpc-4042	35	22	.	.	PUNCT
dpc-4042	36	1	abbreviations	abbreviation	NOUN
dpc-4042	36	2	:	:	PUNCT
dpc-4042	36	3	alt	alt	ADJ
dpc-4042	36	4	:	:	PUNCT
dpc-4042	36	5	alanine	alanine	NOUN
dpc-4042	36	6	aminotransferase	aminotransferase	NOUN
dpc-4042	36	7	;	;	PUNCT
dpc-4042	36	8	ast	ast	NOUN
dpc-4042	36	9	:	:	PUNCT
dpc-4042	36	10	aspartate	aspartate	NOUN
dpc-4042	36	11	aminotransferase	aminotransferase	NOUN
dpc-4042	36	12	;	;	PUNCT
dpc-4042	36	13	cbc	cbc	NOUN
dpc-4042	36	14	:	:	PUNCT
dpc-4042	36	15	complete	complete	ADJ
dpc-4042	36	16	blood	blood	NOUN
dpc-4042	36	17	count	count	NOUN
dpc-4042	36	18	;	;	PUNCT
dpc-4042	36	19	cri	cri	ADJ
dpc-4042	36	20	:	:	PUNCT
dpc-4042	36	21	chronic	chronic	ADJ
dpc-4042	36	22	renal	renal	ADJ
dpc-4042	36	23	insufficiency	insufficiency	NOUN
dpc-4042	36	24	.	.	PUNCT
dpc-4042	37	1	research	research	NOUN
dpc-4042	37	2	letter	letter	NOUN
dpc-4042	37	3	|	|	ADV
dpc-4042	37	4	dermatol	dermatol	ADJ
dpc-4042	37	5	pract	pract	NOUN
dpc-4042	37	6	concept	concept	NOUN
dpc-4042	37	7	.	.	PUNCT
dpc-4042	38	1	2024;14(2):e2024137	2024;14(2):e2024137	NUM
dpc-4042	38	2	3	3	NUM
dpc-4042	38	3	in	in	ADP
dpc-4042	38	4	renally	renally	ADV
dpc-4042	38	5	impaired	impair	VERB
dpc-4042	38	6	patients	patient	NOUN
dpc-4042	38	7	[	[	X
dpc-4042	38	8	1	1	NUM
dpc-4042	38	9	]	]	PUNCT
dpc-4042	38	10	,	,	PUNCT
dpc-4042	38	11	with	with	ADP
dpc-4042	38	12	a	a	DET
dpc-4042	38	13	paucity	paucity	NOUN
dpc-4042	38	14	of	of	ADP
dpc-4042	38	15	studies	study	NOUN
dpc-4042	38	16	to	to	PART
dpc-4042	38	17	support	support	VERB
dpc-4042	38	18	this	this	DET
dpc-4042	38	19	recommendation	recommendation	NOUN
dpc-4042	38	20	.	.	PUNCT
dpc-4042	39	1	in	in	ADP
dpc-4042	39	2	a	a	DET
dpc-4042	39	3	retrospective	retrospective	ADJ
dpc-4042	39	4	study	study	NOUN
dpc-4042	39	5	of	of	ADP
dpc-4042	39	6	13	13	NUM
dpc-4042	39	7	 	 	SPACE
dpc-4042	39	8	kidney	kidney	NOUN
dpc-4042	39	9	transplant	transplant	NOUN
dpc-4042	39	10	recipients	recipient	NOUN
dpc-4042	39	11	(	(	PUNCT
dpc-4042	39	12	creatinine	creatinine	NOUN
dpc-4042	39	13	<	<	X
dpc-4042	39	14	3.39	3.39	NUM
dpc-4042	39	15	mg	mg	PROPN
dpc-4042	39	16	/	/	SYM
dpc-4042	39	17	dl	dl	AUX
dpc-4042	39	18	)	)	PUNCT
dpc-4042	39	19	treated	treat	VERB
dpc-4042	39	20	with	with	ADP
dpc-4042	39	21	terbinafine	terbinafine	NOUN
dpc-4042	39	22	(	(	PUNCT
dpc-4042	39	23	250	250	NUM
dpc-4042	39	24	mg	mg	NOUN
dpc-4042	39	25	daily	daily	ADV
dpc-4042	39	26	,	,	PUNCT
dpc-4042	39	27	12	12	NUM
dpc-4042	39	28	weeks	week	NOUN
dpc-4042	39	29	)	)	PUNCT
dpc-4042	39	30	for	for	ADP
dpc-4042	39	31	onychomycosis	onychomycosis	NOUN
dpc-4042	39	32	,	,	PUNCT
dpc-4042	39	33	none	none	NOUN
dpc-4042	39	34	had	have	VERB
dpc-4042	39	35	hepatic	hepatic	ADJ
dpc-4042	39	36	or	or	CCONJ
dpc-4042	39	37	hematologic	hematologic	ADJ
dpc-4042	39	38	abnormalities	abnormality	NOUN
dpc-4042	39	39	,	,	PUNCT
dpc-4042	39	40	suggesting	suggest	VERB
dpc-4042	39	41	that	that	SCONJ
dpc-4042	39	42	terbinafine	terbinafine	NOUN
dpc-4042	39	43	may	may	AUX
dpc-4042	39	44	be	be	AUX
dpc-4042	39	45	safe	safe	ADJ
dpc-4042	39	46	even	even	ADV
dpc-4042	39	47	in	in	ADP
dpc-4042	39	48	patients	patient	NOUN
dpc-4042	39	49	with	with	ADP
dpc-4042	39	50	severely	severely	ADV
dpc-4042	39	51	reduced	reduce	VERB
dpc-4042	39	52	kidney	kidney	NOUN
dpc-4042	39	53	function	function	NOUN
dpc-4042	39	54	[	[	X
dpc-4042	39	55	4	4	NUM
dpc-4042	39	56	]	]	PUNCT
dpc-4042	39	57	.	.	PUNCT
dpc-4042	40	1	limitations	limitation	NOUN
dpc-4042	40	2	include	include	VERB
dpc-4042	40	3	small	small	ADJ
dpc-4042	40	4	sample	sample	NOUN
dpc-4042	40	5	size	size	NOUN
dpc-4042	40	6	,	,	PUNCT
dpc-4042	40	7	confounding	confound	VERB
dpc-4042	40	8	bias	bias	NOUN
dpc-4042	40	9	,	,	PUNCT
dpc-4042	40	10	single	single	ADJ
dpc-4042	40	11	-	-	PUNCT
dpc-4042	40	12	center	center	NOUN
dpc-4042	40	13	design	design	NOUN
dpc-4042	40	14	,	,	PUNCT
dpc-4042	40	15	and	and	CCONJ
dpc-4042	40	16	lack	lack	NOUN
dpc-4042	40	17	of	of	ADP
dpc-4042	40	18	consideration	consideration	NOUN
dpc-4042	40	19	of	of	ADP
dpc-4042	40	20	dosage	dosage	NOUN
dpc-4042	40	21	and	and	CCONJ
dpc-4042	40	22	adverse	adverse	ADJ
dpc-4042	40	23	event	event	NOUN
dpc-4042	40	24	-	-	PUNCT
dpc-4042	40	25	related	relate	VERB
dpc-4042	40	26	treatment	treatment	NOUN
dpc-4042	40	27	interruptions	interruption	NOUN
dpc-4042	40	28	.	.	PUNCT
dpc-4042	41	1	few	few	ADJ
dpc-4042	41	2	patients	patient	NOUN
dpc-4042	41	3	had	have	VERB
dpc-4042	41	4	severe	severe	ADJ
dpc-4042	41	5	renal	renal	ADJ
dpc-4042	41	6	impairment	impairment	NOUN
dpc-4042	41	7	.	.	PUNCT
dpc-4042	42	1	conclusions	conclusion	NOUN
dpc-4042	42	2	in	in	ADP
dpc-4042	42	3	sum	sum	NOUN
dpc-4042	42	4	,	,	PUNCT
dpc-4042	42	5	onychomycosis	onychomycosis	NOUN
dpc-4042	42	6	patients	patient	NOUN
dpc-4042	42	7	with	with	ADP
dpc-4042	42	8	mild	mild	ADJ
dpc-4042	42	9	to	to	ADP
dpc-4042	42	10	moderate	moderate	ADJ
dpc-4042	42	11	reduced	reduce	VERB
dpc-4042	42	12	kidney	kidney	NOUN
dpc-4042	42	13	function	function	NOUN
dpc-4042	42	14	do	do	AUX
dpc-4042	42	15	not	not	PART
dpc-4042	42	16	seem	seem	VERB
dpc-4042	42	17	to	to	PART
dpc-4042	42	18	have	have	AUX
dpc-4042	42	19	increased	increase	VERB
dpc-4042	42	20	risk	risk	NOUN
dpc-4042	42	21	of	of	ADP
dpc-4042	42	22	developing	develop	VERB
dpc-4042	42	23	laboratory	laboratory	NOUN
dpc-4042	42	24	abnormalities	abnormality	NOUN
dpc-4042	42	25	with	with	ADP
dpc-4042	42	26	terbinafine	terbinafine	ADJ
dpc-4042	42	27	treatment	treatment	NOUN
dpc-4042	42	28	,	,	PUNCT
dpc-4042	42	29	and	and	CCONJ
dpc-4042	42	30	dose	dose	NOUN
dpc-4042	42	31	reduction	reduction	NOUN
dpc-4042	42	32	may	may	AUX
dpc-4042	42	33	not	not	PART
dpc-4042	42	34	be	be	AUX
dpc-4042	42	35	necessary	necessary	ADJ
dpc-4042	42	36	.	.	PUNCT
dpc-4042	43	1	we	we	PRON
dpc-4042	43	2	recommend	recommend	VERB
dpc-4042	43	3	checking	check	VERB
dpc-4042	43	4	baseline	baseline	NOUN
dpc-4042	43	5	creatinine	creatinine	NOUN
dpc-4042	43	6	to	to	PART
dpc-4042	43	7	evaluate	evaluate	VERB
dpc-4042	43	8	renal	renal	ADJ
dpc-4042	43	9	function	function	NOUN
dpc-4042	43	10	before	before	ADP
dpc-4042	43	11	prescribing	prescribe	VERB
dpc-4042	43	12	terbinafine	terbinafine	NOUN
dpc-4042	43	13	for	for	ADP
dpc-4042	43	14	onychomycosis	onychomycosis	NOUN
dpc-4042	43	15	treatment	treatment	NOUN
dpc-4042	43	16	,	,	PUNCT
dpc-4042	43	17	pending	pende	VERB
dpc-4042	43	18	larger	large	ADJ
dpc-4042	43	19	multicenter	multicenter	NOUN
dpc-4042	43	20	trials	trial	NOUN
dpc-4042	43	21	evaluating	evaluate	VERB
dpc-4042	43	22	onychomycosis	onychomycosis	NOUN
dpc-4042	43	23	patients	patient	NOUN
dpc-4042	43	24	with	with	ADP
dpc-4042	43	25	kidney	kidney	NOUN
dpc-4042	43	26	disease	disease	NOUN
dpc-4042	43	27	.	.	PUNCT
dpc-4042	44	1	references	reference	NOUN
dpc-4042	44	2	1	1	NUM
dpc-4042	44	3	.	.	PUNCT
dpc-4042	45	1	lamisil	lamisil	ADJ
dpc-4042	45	2	oral	oral	ADJ
dpc-4042	45	3	tablets	tablet	NOUN
dpc-4042	45	4	,	,	PUNCT
dpc-4042	45	5	terbinafine	terbinafine	NOUN
dpc-4042	45	6	hcl	hcl	PROPN
dpc-4042	45	7	oral	oral	ADJ
dpc-4042	45	8	tablets	tablet	NOUN
dpc-4042	46	1	[	[	X
dpc-4042	46	2	package	package	NOUN
dpc-4042	46	3	insert	insert	NOUN
dpc-4042	46	4	]	]	PUNCT
dpc-4042	46	5	.	.	PUNCT
dpc-4042	47	1	east	east	PROPN
dpc-4042	47	2	hanover	hanover	PROPN
dpc-4042	47	3	,	,	PUNCT
dpc-4042	47	4	nj	nj	PROPN
dpc-4042	47	5	:	:	PUNCT
dpc-4042	47	6	novartis	novartis	NOUN
dpc-4042	47	7	pharmaceuticals	pharmaceutical	NOUN
dpc-4042	47	8	corporation	corporation	NOUN
dpc-4042	47	9	;	;	PUNCT
dpc-4042	47	10	2017	2017	NUM
dpc-4042	47	11	.	.	X
dpc-4042	48	1	2	2	X
dpc-4042	48	2	.	.	X
dpc-4042	48	3	elewski	elewski	PROPN
dpc-4042	48	4	b	b	PROPN
dpc-4042	48	5	,	,	PUNCT
dpc-4042	48	6	tavakkol	tavakkol	VERB
dpc-4042	48	7	a.	a.	NOUN
dpc-4042	48	8	safety	safety	NOUN
dpc-4042	48	9	and	and	CCONJ
dpc-4042	48	10	tolerability	tolerability	NOUN
dpc-4042	48	11	of	of	ADP
dpc-4042	48	12	oral	oral	ADJ
dpc-4042	48	13	antifungal	antifungal	ADJ
dpc-4042	48	14	agents	agent	NOUN
dpc-4042	48	15	in	in	ADP
dpc-4042	48	16	the	the	DET
dpc-4042	48	17	treatment	treatment	NOUN
dpc-4042	48	18	of	of	ADP
dpc-4042	48	19	fungal	fungal	ADJ
dpc-4042	48	20	nail	nail	NOUN
dpc-4042	48	21	disease	disease	NOUN
dpc-4042	48	22	:	:	PUNCT
dpc-4042	48	23	a	a	DET
dpc-4042	48	24	proven	prove	VERB
dpc-4042	48	25	reality	reality	NOUN
dpc-4042	48	26	.	.	PUNCT
dpc-4042	49	1	ther	ther	PROPN
dpc-4042	49	2	clin	clin	PROPN
dpc-4042	49	3	risk	risk	NOUN
dpc-4042	49	4	manag	manag	PROPN
dpc-4042	49	5	.	.	PUNCT
dpc-4042	50	1	2005	2005	NUM
dpc-4042	50	2	dec;1(4):299	dec;1(4):299	PROPN
dpc-4042	50	3	-	-	PUNCT
dpc-4042	50	4	306	306	NUM
dpc-4042	50	5	.	.	PUNCT
dpc-4042	51	1	3	3	X
dpc-4042	51	2	.	.	X
dpc-4042	51	3	filho	filho	PROPN
dpc-4042	51	4	ams	ams	PROPN
dpc-4042	51	5	,	,	PUNCT
dpc-4042	51	6	ventura	ventura	PROPN
dpc-4042	51	7	cg	cg	PROPN
dpc-4042	51	8	,	,	PUNCT
dpc-4042	51	9	criado	criado	X
dpc-4042	51	10	pr	pr	NOUN
dpc-4042	51	11	,	,	PUNCT
dpc-4042	51	12	del	del	PROPN
dpc-4042	51	13	negro	negro	PROPN
dpc-4042	51	14	gb	gb	PROPN
dpc-4042	51	15	,	,	PUNCT
dpc-4042	51	16	freitas	freita	NOUN
dpc-4042	51	17	rs	rs	PROPN
dpc-4042	51	18	,	,	PUNCT
dpc-4042	51	19	luiz	luiz	PROPN
dpc-4042	51	20	oc	oc	PROPN
dpc-4042	51	21	,	,	PUNCT
dpc-4042	51	22	giudice	giudice	PROPN
dpc-4042	51	23	mc	mc	PROPN
dpc-4042	51	24	,	,	PUNCT
dpc-4042	51	25	neto	neto	PROPN
dpc-4042	51	26	ed	ed	PROPN
dpc-4042	51	27	,	,	PUNCT
dpc-4042	51	28	benard	benard	NOUN
dpc-4042	51	29	g.	g.	NOUN
dpc-4042	51	30	hemodialysis	hemodialysis	NOUN
dpc-4042	51	31	and	and	CCONJ
dpc-4042	51	32	kidney	kidney	NOUN
dpc-4042	51	33	transplantation	transplantation	NOUN
dpc-4042	51	34	as	as	ADP
dpc-4042	51	35	predisposing	predispose	VERB
dpc-4042	51	36	conditions	condition	NOUN
dpc-4042	51	37	to	to	PART
dpc-4042	51	38	onychomycosis	onychomycosis	VERB
dpc-4042	51	39	.	.	PUNCT
dpc-4042	52	1	nephron	nephron	NOUN
dpc-4042	52	2	.	.	PUNCT
dpc-4042	53	1	2017;137(1):38	2017;137(1):38	PROPN
dpc-4042	53	2	-	-	PUNCT
dpc-4042	53	3	46	46	NUM
dpc-4042	53	4	.	.	NOUN
dpc-4042	54	1	4	4	NUM
dpc-4042	54	2	.	.	X
dpc-4042	54	3	stolmeier	stolmeier	NOUN
dpc-4042	54	4	da	da	PROPN
dpc-4042	54	5	,	,	PUNCT
dpc-4042	54	6	stratman	stratman	NOUN
dpc-4042	54	7	hb	hb	PROPN
dpc-4042	54	8	,	,	PUNCT
dpc-4042	54	9	mcintee	mcintee	NOUN
dpc-4042	54	10	tj	tj	NOUN
dpc-4042	54	11	,	,	PUNCT
dpc-4042	54	12	stratman	stratman	NOUN
dpc-4042	54	13	ej	ej	PROPN
dpc-4042	54	14	.	.	PROPN
dpc-4042	54	15	utility	utility	NOUN
dpc-4042	54	16	of	of	ADP
dpc-4042	54	17	laboratory	laboratory	NOUN
dpc-4042	54	18	test	test	NOUN
dpc-4042	54	19	result	result	NOUN
dpc-4042	54	20	monitoring	monitoring	NOUN
dpc-4042	54	21	in	in	ADP
dpc-4042	54	22	patients	patient	NOUN
dpc-4042	54	23	taking	take	VERB
dpc-4042	54	24	oral	oral	ADJ
dpc-4042	54	25	terbinafine	terbinafine	NOUN
dpc-4042	54	26	or	or	CCONJ
dpc-4042	54	27	griseofulvin	griseofulvin	NOUN
dpc-4042	54	28	for	for	ADP
dpc-4042	54	29	dermatophyte	dermatophyte	NOUN
dpc-4042	54	30	infections	infection	NOUN
dpc-4042	54	31	.	.	PUNCT
dpc-4042	55	1	jama	jama	PROPN
dpc-4042	55	2	dermatol	dermatol	NOUN
dpc-4042	55	3	.	.	PUNCT
dpc-4042	56	1	2018	2018	NUM
dpc-4042	56	2	dec	dec	PROPN
dpc-4042	56	3	1;154(12):1409	1;154(12):1409	PROPN
dpc-4042	56	4	-	-	PROPN
dpc-4042	56	5	1416	1416	NUM
dpc-4042	56	6	.	.	PUNCT
dpc-4042	57	1	5	5	X
dpc-4042	57	2	.	.	X
dpc-4042	57	3	kao	kao	PROPN
dpc-4042	57	4	wy	wy	PROPN
dpc-4042	57	5	,	,	PUNCT
dpc-4042	57	6	su	su	PROPN
dpc-4042	57	7	cw	cw	PROPN
dpc-4042	57	8	,	,	PUNCT
dpc-4042	57	9	huang	huang	PROPN
dpc-4042	57	10	ys	ys	PROPN
dpc-4042	57	11	,	,	PUNCT
dpc-4042	57	12	chou	chou	PROPN
dpc-4042	57	13	yc	yc	PROPN
dpc-4042	57	14	,	,	PUNCT
dpc-4042	57	15	chen	chen	PROPN
dpc-4042	57	16	yc	yc	PROPN
dpc-4042	57	17	,	,	PUNCT
dpc-4042	57	18	chung	chung	PROPN
dpc-4042	57	19	wh	wh	PROPN
dpc-4042	57	20	,	,	PUNCT
dpc-4042	57	21	hou	hou	PROPN
dpc-4042	57	22	mc	mc	PROPN
dpc-4042	57	23	,	,	PUNCT
dpc-4042	57	24	lin	lin	PROPN
dpc-4042	57	25	hc	hc	PROPN
dpc-4042	57	26	,	,	PUNCT
dpc-4042	57	27	lee	lee	PROPN
dpc-4042	57	28	fy	fy	PROPN
dpc-4042	57	29	,	,	PUNCT
dpc-4042	57	30	wu	wu	PROPN
dpc-4042	57	31	jc	jc	PROPN
dpc-4042	57	32	.	.	PROPN
dpc-4042	57	33	risk	risk	NOUN
dpc-4042	57	34	of	of	ADP
dpc-4042	57	35	oral	oral	ADJ
dpc-4042	57	36	antifungal	antifungal	ADJ
dpc-4042	57	37	agent	agent	NOUN
dpc-4042	57	38	-	-	PUNCT
dpc-4042	57	39	induced	induce	VERB
dpc-4042	57	40	liver	liver	NOUN
dpc-4042	57	41	injury	injury	NOUN
dpc-4042	57	42	in	in	ADP
dpc-4042	57	43	taiwanese	taiwanese	PROPN
dpc-4042	57	44	.	.	PUNCT
dpc-4042	58	1	br	br	PROPN
dpc-4042	59	1	j	j	PROPN
dpc-4042	59	2	clin	clin	PROPN
dpc-4042	59	3	pharmacol	pharmacol	PROPN
dpc-4042	59	4	.	.	PUNCT
dpc-4042	60	1	2014	2014	NUM
dpc-4042	60	2	jan;77(1):180	jan;77(1):180	PROPN
dpc-4042	60	3	-	-	PUNCT
dpc-4042	60	4	9	9	NUM
dpc-4042	60	5	.	.	NOUN
dpc-4042	61	1	6	6	NUM
dpc-4042	61	2	.	.	PUNCT
dpc-4042	61	3	moreno	moreno	PROPN
dpc-4042	61	4	-	-	PUNCT
dpc-4042	61	5	sabater	sabater	PROPN
dpc-4042	61	6	a	a	PRON
dpc-4042	61	7	,	,	PUNCT
dpc-4042	61	8	ouali	ouali	ADJ
dpc-4042	61	9	n	n	CCONJ
dpc-4042	61	10	,	,	PUNCT
dpc-4042	61	11	chasset	chasset	VERB
dpc-4042	61	12	f	f	PROPN
dpc-4042	61	13	,	,	PUNCT
dpc-4042	61	14	frances	frances	PROPN
dpc-4042	61	15	c	c	PROPN
dpc-4042	61	16	,	,	PUNCT
dpc-4042	61	17	senet	senet	PROPN
dpc-4042	61	18	p	p	NOUN
dpc-4042	61	19	,	,	PUNCT
dpc-4042	61	20	faucon	faucon	NOUN
dpc-4042	61	21	c	c	NOUN
dpc-4042	61	22	,	,	PUNCT
dpc-4042	61	23	hennequin	hennequin	PROPN
dpc-4042	61	24	c	c	NOUN
dpc-4042	61	25	,	,	PUNCT
dpc-4042	61	26	bachmeyer	bachmeyer	PROPN
dpc-4042	61	27	c.	c.	PROPN
dpc-4042	61	28	severe	severe	ADJ
dpc-4042	61	29	onychomycosis	onychomycosis	NOUN
dpc-4042	61	30	management	management	NOUN
dpc-4042	61	31	with	with	ADP
dpc-4042	61	32	oral	oral	ADJ
dpc-4042	61	33	terbinafine	terbinafine	NOUN
dpc-4042	61	34	in	in	ADP
dpc-4042	61	35	a	a	DET
dpc-4042	61	36	kidney	kidney	NOUN
dpc-4042	61	37	transplantation	transplantation	NOUN
dpc-4042	61	38	setting	setting	NOUN
dpc-4042	61	39	:	:	PUNCT
dpc-4042	61	40	clinical	clinical	ADJ
dpc-4042	61	41	follow	follow	NOUN
dpc-4042	61	42	-	-	PUNCT
dpc-4042	61	43	up	up	NOUN
dpc-4042	61	44	by	by	ADP
dpc-4042	61	45	image	image	NOUN
dpc-4042	61	46	analysis	analysis	NOUN
dpc-4042	61	47	.	.	PUNCT
dpc-4042	62	1	mycoses	mycose	NOUN
dpc-4042	62	2	.	.	PUNCT
dpc-4042	63	1	2021	2021	NUM
dpc-4042	63	2	mar;64(3):309	mar;64(3):309	NOUN
dpc-4042	63	3	-	-	PUNCT
dpc-4042	63	4	315	315	NUM
dpc-4042	63	5	.	.	PUNCT